Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells

REFERENCES

• Amann, J. M., Nip J., Strom D. K., Lutterbach B., Harada H., Lenny N., Downing J. R., Meyers S., and Hiebert S. W.. 2001. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21:6470–6483.
   PubMed Web of Science ®Google Scholar
• Austin, T. W., Solar G. P., Ziegler F. C., Liem L., and Matthews W.. 1997. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood 89:3624–3635.
   PubMed Web of Science ®Google Scholar
• Benoit, G., Altucci L., Flexor M., Ruchaud S., Lillehaug J., Raffelsberger W., Gronemeyer H., and Lanotte M.. 1999. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18:7011–7018.
   PubMed Web of Science ®Google Scholar
• Brandon, C., Eisenberg L. M., and Eisenberg C. A.. 2000. WNT signaling modulates the diversification of hematopoietic cells. Blood 96:4132–4141.
   PubMed Web of Science ®Google Scholar
• Burel, S. A., Harakawa N., Zhou L., Pabst T., Tenen D. G., and Zhang D. E.. 2001. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol. Cell. Biol. 21:5577–5590.
   PubMed Web of Science ®Google Scholar
• Claverie, J. M. 1999. Computational methods for the identification of differential and coordinated gene expression. Hum. Mol. Genet. 8:1821–1832.
   PubMed Web of Science ®Google Scholar
• Cooper, C. L., and Newburger P. E.. 1998. Differential expression of Id genes in multipotent myeloid progenitor cells: Id-1 is induced by early-and late-acting cytokines while Id-2 is selectively induced by cytokines that drive terminal granulocytic differentiation. J. Cell. Biochem. 71:277–285.
   PubMedGoogle Scholar
• Dorsky, R. I., Moon R. T., and Raible D. W.. 1998. Control of neural crest cell fate by the Wnt signalling pathway. Nature 396:370–373.
   PubMed Web of Science ®Google Scholar
• Easwaran, V., Pishvaian M., Salimuddin, and Byers S.. 1999. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr. Biol. 9:1415–1418.
   PubMed Web of Science ®Google Scholar
• Ferrara, F. F., Fazi F., Bianchini A., Padula F., Gelmetti V., Minucci S., Mancini M., Pelicci P. G., Lo Coco F., and Nervi C.. 2001. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61:2–7.
   PubMed Web of Science ®Google Scholar
• Gelmetti, V., Zhang J., Fanelli M., Minucci S., Pelicci P. G., and Lazar M. A.. 1998. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell. Biol. 18:7185–7191.
   PubMed Web of Science ®Google Scholar
• Grignani, F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F. F., Zamir I., Seiser C., Lazar M. A., Minucci S., and Pelicci P. G.. 1998. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815–818.
   PubMed Web of Science ®Google Scholar
• Grignani, F., Ferrucci P. F., Testa U., Talamo G., Fagioli M., Alcalay M., Mencarelli A., Peschle C., Nicoletti I., and Pelicci P. G.. 1993. The acute promyelocytic leukaemia specific PML/RARa fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423–429.
   PubMed Web of Science ®Google Scholar
• Grignani, F., Kinsella T., Mencarelli A., Valtieri M., Riganelli D., Lanfrancone L., Peschle C., Nolan G. P., and Pelicci P. G.. 1998. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 58:14–19.
   PubMed Web of Science ®Google Scholar
• Grisolano, J. L., Wesselschmidt R. L., Pelicci P. G., and Ley T. J.. 1997. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376–387.
   PubMed Web of Science ®Google Scholar
• He, T. C., Sparks A. B., Rago C., Hermeking H., Zawel L., da Costa L. T., Morin P. J., Vogelstein B., and Kinzler K. W.. 1998. Identification of c-MYC as a target of the APC pathway. Science 281:1509–1512.
   PubMed Web of Science ®Google Scholar
• Higuchi, M., O'Brien D., Kumaravelu P., Lenny N., Yeoh E. J., and Downing J. R.. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1:63–74.
   PubMed Web of Science ®Google Scholar
• Ishiguro, A., Spirin K. S., Shiohara M., Tobler A., Gombart A. F., Israel M. A., Norton J. D., and Koeffler H. P.. 1996. Id2 expression increases with differentiation of human myeloid cells. Blood 87:5225–5231.
   PubMedGoogle Scholar
• Johansen, L. M., Iwama A., Lodie T. A., Sasaki K., Felsher D. W., Golub T. R., and Tenen D. G.. 2001. c-Myc is a critical target for c/EBPα in granulopoiesis. Mol. Cell. Biol. 21:3789–3806.
   PubMed Web of Science ®Google Scholar
• Kai, H., Hisatsune A., Chihara T., Uto A., Kokusho A., Miyata T., and Basbaum C.. 1999. Myeloid ELF-1-like factor up-regulates lysozyme transcription in epithelial cells. J. Biol. Chem. 274:20098–20102.
   PubMedGoogle Scholar
• Kirmizis, A., Bartley S. M., and Farnham P. J.. 2003. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol. Cancer Ther. 2:113–121.
   PubMed Web of Science ®Google Scholar
• Kolligs, F. T., Kolligs B., Hajra K. M., Hu G., Tani M., Cho K. R., and Fearon E. R.. 2000. gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev. 14:1319–1331.
   PubMed Web of Science ®Google Scholar
• Kozopas, K. M., Samos C. H., and Nusse R.. 1998. DWnt-2, a Drosophila Wnt gene required for the development of the male reproductive tract, specifies a sexually dimorphic cell fate. Genes Dev. 12:1155–1165.
   PubMedGoogle Scholar
• Licht, J. D. 2001. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20:5660–5679.
   PubMed Web of Science ®Google Scholar
• Linggi, B., Müller-Tidow C., Van De Locht L., Hu M., Nip J., Serve H., Berdel W. E., Van Der Reijden B., Quelle D. E., Rowley J. D., Cleveland J., Jansen J. H., Pandolfi P. P., and Hiebert S. W.. 2002. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat. Med. 8:743–750.
   PubMed Web of Science ®Google Scholar
• Look, A. T. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278:1059–1064.
   PubMed Web of Science ®Google Scholar
• Mao, S., Frank R. C., Zhang J., Miyazaki Y., and Nimer S. D.. 1999. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol. Cell. Biol. 19:3635–3644.
   PubMed Web of Science ®Google Scholar
• Mariadason, J. M., Corner G. A., and Augenlicht L. H.. 2000. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60:4561–4572.
   PubMed Web of Science ®Google Scholar
• Melnick, A., Carlile G. W., McConnell M. J., Polinger A., Hiebert S. W., and Licht J. D.. 2000. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood 96:3939–3947.
   PubMed Web of Science ®Google Scholar
• Melnick, A., and Licht J. D.. 1999. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167–3215.
   PubMed Web of Science ®Google Scholar
• Miller, J. R., and Moon R. T.. 1997. Analysis of the signaling activities of localization mutants of beta-catenin during axis specification in Xenopus. J. Cell Biol. 139:229–243.
   PubMed Web of Science ®Google Scholar
• Minucci, S., Maccarana M., Cioce M., De Luca P., Gelmetti V., Segalla S., Di Croce L., Giavara S., Matteucci C., Gobbi A., Bianchini A., Colombo E., Schiavoni I., Badaracco G., Hu X., Lazar M. A., Landsberger N., Nervi C., and Pelicci P. G.. 2000. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5:811–820.
   PubMed Web of Science ®Google Scholar
• Miyazaki, Y., Sun X., Uchida H., Zhang J., and Nimer S.. 1996. MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties. Oncogene 13:1721–1729.
   PubMed Web of Science ®Google Scholar
• Mizuki, M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C., Gruning W., Kratz-Albers K., Serve S., Steur C., Buchner T., Kienast J., Kanakura Y., Berdel W. E., and Serve H.. 2000. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96:3907–3914.
   PubMed Web of Science ®Google Scholar
• Müller, C., Readhead C., Diederichs S., Idos G., Yang R., Tidow N., Serve H., Berdel W. E., and Koeffler H. P.. 2000. Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent. Mol. Cell. Biol. 20:3316–3329.
   PubMedGoogle Scholar
• Müller, C., Yang R., Park D. J., Serve H., Berdel W. E., and Koeffler H. P.. 2000. The aberrant fusion proteins PML-RAR alpha and PLZF-RAR alpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia. Blood 96:3894–3899.
   PubMed Web of Science ®Google Scholar
• Müller-Tidow, C., Metzger R., Kügler K., Diederichs S., Idos G., Thomas M., Dockhorn-Dworniczak B., Schneider P. M., Koeffler H. P., Berdel W. E., and Serve H.. 2001. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 61:647–653.
   PubMed Web of Science ®Google Scholar
• Müller-Tidow, C., Wang W., Idos G. E., Diederichs S., Yang R., Readhead C., Berdel W. E., Serve H., Saville M., Watson R., and Koeffler H. P.. 2001. Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. Blood 97:2091–2097.
   PubMed Web of Science ®Google Scholar
• Mulloy, J. C., Cammenga J., MacKenzie K. L., Berguido F. J., Moore M. A., and Nimer S. D.. 2002. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 99:15–23.
   PubMed Web of Science ®Google Scholar
• Murdoch, B., Chadwick K., Martin M., Shojaei F., Shah K. V., Gallacher L., Moon R. T., and Bhatia M.. 2003. Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo. Proc. Natl. Acad. Sci. USA 100:3422–3427.
   PubMed Web of Science ®Google Scholar
• Pabst, T., Mueller B. U., Harakawa N., Schoch C., Haferlach T., Behre G., Hiddemann W., Zhang D. E., and Tenen D. G.. 2001. AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nat. Med. 7:444–451.
   PubMed Web of Science ®Google Scholar
• Pabst, T., Mueller B. U., Zhang P., Radomska H. S., Narravula S., Schnittger S., Behre G., Hiddemann W., and Tenen D. G.. 2001. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPα), in acute myeloid leukemia. Nat. Genet. 27:263–270.
   PubMed Web of Science ®Google Scholar
• Polakis, P. 2000. Wnt signaling and cancer. Genes Dev. 14:1837–1851.
   PubMed Web of Science ®Google Scholar
• Potter, E., Braun S., Lehmann U., and Brabant G.. 2001. Molecular cloning of a functional promoter of the human plakoglobin gene. Eur. J. Endocrinol. 145:625–633.
   PubMedGoogle Scholar
• Radomska, H. S., Huettner C. S., Zhang P., Cheng T., Scadden D. T., and Tenen D. G.. 1998. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol. Cell. Biol. 18:4301–4314.
   PubMed Web of Science ®Google Scholar
• Reya, T., Duncan A. W., Ailles L., Domen J., Scherer D. C., Willert K., Hintz L., Nusse R., and Weissman I. L.. 2003. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423:409–414.
   PubMed Web of Science ®Google Scholar
• Ross, S. E., Hemati N., Longo K. A., Bennett C. N., Lucas P. C., Erickson R. L., and MacDougald O. A.. 2000. Inhibition of adipogenesis by Wnt signaling. Science 289:950–953.
   PubMed Web of Science ®Google Scholar
• Ruthardt, M., Testa U., Nervi C., Ferrucci P. F., Grignani F., Puccetti E., Peschle C., and Pelicci P. G.. 1997. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RARα) and PLZF-RARα fusion proteins on retinoic acid signaling. Mol. Cell. Biol. 17:4859–4869.
   PubMed Web of Science ®Google Scholar
• Sadot, E., Simcha I., Iwai K., Ciechanover A., Geiger B., and Ben-Ze'ev A.. 2000. Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system. Oncogene 19:1992–2001.
   PubMed Web of Science ®Google Scholar
• Shtutman, M., Zhurinsky J., Oren M., Levina E., and Ben-Ze'ev A.. 2002. PML is a target gene of beta-catenin and plakoglobin, and coactivates beta-catenin-mediated transcription. Cancer Res. 62:5947–5954.
   PubMedGoogle Scholar
• Simcha, I., Shtutman M., Salomon D., Zhurinsky J., Sadot E., Geiger B., and Ben-Ze'ev A.. 1998. Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J. Cell Biol. 141:1433–1448.
   PubMed Web of Science ®Google Scholar
• Tenen, D. G. 2001. Abnormalities of the CEBP alpha transcription factor: a major target in acute myeloid leukemia. Leukemia 15:688–689.
   PubMed Web of Science ®Google Scholar
• Tetsu, O., and McCormick F.. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–426.
   PubMed Web of Science ®Google Scholar
• Tonks, A., Pearn L., Tonks A. J., Pearce L., Hoy T., Phillips S., Fisher J., Downing J. R., Burnett A. K., and Darley R. L.. 2002. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 22:22.
   Google Scholar
• Tusher, V. G., Tibshirani R., and Chu G.. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98:5116–5121.
   PubMed Web of Science ®Google Scholar
• Weinmann, A. S., Bartley S. M., Zhang T., Zhang M. Q., and Farnham P. J.. 2001. Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol. Cell. Biol. 21:6820–6832.
   PubMed Web of Science ®Google Scholar
• Westendorf, J. J., Yamamoto C. M., Lenny N., Downing J. R., Selsted M. E., and Hiebert S. W.. 1998. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol. Cell. Biol. 18:322–333.
   PubMed Web of Science ®Google Scholar
• Yuan, Y., Zhou L., Miyamoto T., Iwasaki H., Harakawa N., Hetherington C. J., Burel S. A., Lagasse E., Weissman I. L., Akashi K., and Zhang D. E.. 2001. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc. Natl. Acad. Sci. USA 98:10398–10403.
   PubMed Web of Science ®Google Scholar
• Zhang, D. E., Zhang P., Wang N. D., Hetherington C. J., Darlington G. J., and Tenen D. G.. 1997. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc. Natl. Acad. Sci. USA 94:569–574.
   PubMed Web of Science ®Google Scholar
• Zhurinsky, J., Shtutman M., and Ben-Ze'ev A.. 2000. Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J. Cell Sci. 113:3127–3139.
   PubMed Web of Science ®Google Scholar